The Journal of pathology · 2025
Mutation profiling in differential diagnosis between TdT-positive high-grade/large B-cell lymphoma and B-lymphoblastic leukaemia/lymphoma.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tzioni Maria-Myrsini, Cucco Francesco, Rásó-Barnett Lívia, Chen Zi, Wotherspoon Andrew, Kurz Katrin S, Madej Ewelina, Makker Jasmine, Strazda Anna E, Guo Fang, Egan Caoimhe, Soilleux Elizabeth, Hook Liz, Krenacs Laszlo, Geyer Julia T, Laurent Camille, Xerri Luc, Mescam Lenaïg, Plank Lukas, Rahbek Gjerdrum Lise Mette, Lopez-Hisijos Nicolas, Greiner Timothy, Khoury Joseph, Klapper Wolfram, Oschlies Ilske, Rosenwald Andreas, Ott German, Du Ming-Qing
Аннотация
Terminal deoxynucleotidyl transferase (TdT) is occasionally expressed in large B-cell lymphoma (LBCL), and this causes difficulty in differential diagnosis from B-lymphoblastic leukaemia/lymphoma (B-ALL/LBL). We reviewed 31 cases of TdT-positive LBCL and B-ALL/LBL, and their final diagnosis included 19 diffuse large/high-grade BCLs with MYC and BCL2 rearrangements (five DLBCL-MYC/BCL2, 14 HGBCL-MYC/BCL2), three DLBCL not otherwise specified (NOS), three HGBCL-NOS, four B-ALL/LBL, and two unclassifiable cases. TdT was variably expressed in all these cases, without any clear demarcation among different groups. Loss or partial loss of CD20 expression was seen in 13/17 DLBCL/HGBCL-MYC/BCL2, 2/3 HGBCL-NOS, and 2/2 unclassified, albeit not in DLBCL-NOS. Expression of BCL6 and/or MUM1 was seen in 3/4 B-ALL/LBLs and 2/2 unclassified. Next-generation sequencing revealed characteristic mutations associated with follicular lymphoma and its high-grade transformation in each DLBCL/HGBCL-MYC/BCL2, and also frequent variants in genes targeted by somatic hypermutation (SHM) in almost all DLBCL/HGBCL-MYC/BCL2, DLBCL-NOS, and HGBCL-NOS but one case. In contrast, such mutations were absent in B-ALL/LBL. There were no pathognomonic mutations in the two unclassifiable cases, although one showed a moderate level of somatic mutations in its rearranged IGHV. Furthermore, in three cases of TdT-positive HGBCL-MYC/BCL2, studies of previous or concurrent follicular lymphoma demonstrated their divergent evolution from an IGH::BCL2-positive cell population following acquisition of MYC translocation. In conclusion, mutation profiling analysis including the SHM target genes is highly valuable in the differential diagnosis between TdT-positive LBCL and B-ALL/LBL. © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
Предметные рубрики MeSH
HumansDiagnosis, DifferentialLymphoma, Large B-Cell, DiffuseFemaleMaleAgedMiddle AgedDNA NucleotidylexotransferaseAdultMutationDNA Mutational AnalysisBiomarkers, TumorAged, 80 and overProto-Oncogene Proteins c-bcl-2Young AdultAdolescentPrecursor Cell Lymphoblastic Leukemia-LymphomaProto-Oncogene Proteins c-myc